Drugs / 18F-MK-6240
18F-MK-6240
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03757910 | Oct 2019 → Jan 2023 | Alzheimer disease | José A. Luchsinger | Terminated | No outcome recorded |
| Phase 0 | NCT03071224 | Jun 2016 → Jun 2021 | Alzheimer disease | Invicro | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT03706261 | Mar 2019 → Jul 2023 | Alzheimer disease | Adam Brickman | Completed | No outcome recorded |
| Phase 1 | NCT02562989 | Oct 2015 → Dec 2016 | Alzheimer disease, amnestic disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04576793 | Nov 2020 → May 2027 expected | Alzheimer disease | Columbia University | Recruiting | No outcome recorded |
| Phase 2 | NCT03389100 | Jul 2018 → Jun 2026 overdue | prediabetes syndrome, type 2 diabetes mellitus | Columbia University | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT03373604 | Dec 2017 → May 2022 | Alzheimer disease | Patrick Lao | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07115238 | Nov 2024 → Dec 2025 overdue | Alzheimer disease | Sinotau Pharmaceutical Group | Recruiting | No outcome recorded |
| Phase 3 | NCT06860373 | Jun 2023 → Apr 2024 | Down syndrome | LuMind IDSC Foundation | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06999434 Background | May 2025 → May 2030 expected | Alzheimer disease, multiple sclerosis, radiculopathy, spinal cord injury | Yale University | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]MK-6240 | “18F-MK-6240 (18F-labeled 6-(fluoro)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine) is a highly selective, subnanomolar-affinity PET tracer for imaging neurofibrillary...” PMID 29880509 ↗ Jun 20189“The overall goal of this protocol is to evaluate \[18F\]MK-6240 (also known as \[18F\]MNI-946) a tau targeted radiopharmaceutical.” NCT03071224 ↗ |
| Known as | [18F]MNI-946 | “The overall goal of this protocol is to evaluate \[18F\]MK-6240 (also known as \[18F\]MNI-946) a tau targeted radiopharmaceutical.” NCT03071224 ↗ |
| Known as | XTR006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07115238 ↗ |
| Modality | Diagnostic / imaging agent | “a Positron Emission Tomography (PET) imaging agent” NCT02562989 ↗ |
| Route | Intravenous | “single intravenous (IV) dose” NCT02562989 ↗ |